<code id='D782653A81'></code><style id='D782653A81'></style>
    • <acronym id='D782653A81'></acronym>
      <center id='D782653A81'><center id='D782653A81'><tfoot id='D782653A81'></tfoot></center><abbr id='D782653A81'><dir id='D782653A81'><tfoot id='D782653A81'></tfoot><noframes id='D782653A81'>

    • <optgroup id='D782653A81'><strike id='D782653A81'><sup id='D782653A81'></sup></strike><code id='D782653A81'></code></optgroup>
        1. <b id='D782653A81'><label id='D782653A81'><select id='D782653A81'><dt id='D782653A81'><span id='D782653A81'></span></dt></select></label></b><u id='D782653A81'></u>
          <i id='D782653A81'><strike id='D782653A81'><tt id='D782653A81'><pre id='D782653A81'></pre></tt></strike></i>

          hotspot

          hotspot

          author:entertainment    Page View:5551
          People in business and medical wardrobe in a table discussion — coverage from STAT
          Adobe

          R1 RCM, a large publicly traded technology company that helps hospitals and physicians collect money from insurers and patients, may be going private.

          Private equity firm New Mountain Capital has offered to purchase R1 for $13.75 per share, or roughly $5.8 billion in cash, according to new financial disclosures filed Monday. New Mountain Capital is R1’s second-largest investor, owning nearly one-third of the company’s shares.

          advertisement

          In response to the offer, R1 asked New Mountain Capital to “engage in good faith discussions” with its largest investor — a partnership between Ascension, the large Catholic hospital system, and private equity firm TowerBrook Capital Partners. New Mountain Capital has since held several in-person meetings with Ascension and TowerBrook throughout February, but maintained its original offer for R1. No deal has been finalized yet.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested
          Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

          ThebacteriumA.baylyiwasengineeredtodetectacommoncancermutation.CourtesyofJosephineWrightDanWorthley,

          read more
          Apple is now the first public company to be valued at $3 trillion
          Apple is now the first public company to be valued at $3 trillion

          6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

          read more

          Amylyx's ALS drug launch starts strong. It could be trouble for FDA

          MollyFerguson/STATBehindthestellarcommerciallaunchofAmylyxPharmaceuticals’treatmentforALSliesanuncom